Patents Assigned to Allergan Sales, Inc.
-
Publication number: 20060154314Abstract: The present invention provides a nucleic acid molecule which contains a nucleotide sequence encoding a SNAP-25 substrate which includes (i) a green fluorescent protein; (ii) a first partner of an affinity couple; and (iii) a portion of SNAP-25 that includes a BoNT/A, BoNT/C1 or BoNT/E recognition sequence containing a cleavage site, where the cleavage site intervenes between the green fluorescent protein and the first partner of the affinity couple. Further provided herein is a nucleic acid molecule which contains a nucleotide sequence encoding a tagged toxin substrate which includes (i) a fluorescent protein; (ii) a first partner of an affinity couple; and (iii) a clostridial toxin recognition sequence containing a cleavage site, where the cleavage site intervenes between the fluorescent protein and the first partner of the affinity couple.Type: ApplicationFiled: August 13, 2004Publication date: July 13, 2006Applicant: Allergan Sales, Inc.Inventors: Lance Steward, Marcella Gilmore, Kei Aoki
-
Publication number: 20050260230Abstract: Modified neurotoxin comprising neurotoxin including structural modification, wherein the structural modification alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification. In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain.Type: ApplicationFiled: January 8, 2004Publication date: November 24, 2005Applicant: Allergan Sales, Inc.Inventors: Lance Steward, Ester Fernandez-Salas, Todd Herrington, Kei Aoki
-
Publication number: 20050192322Abstract: Glutamate causes migration and proliferation of retinal pigment epithelium and/or glial cells, and glutamate antagonists can prevent, treat or reduce retinal pigment epithelium and/or glial migration and the subsequent development of proliferative vitreoretinopathy. Avoidance or management of proliferative vitreoretinopathy can be achieved by administering to the patient a compound capable of reducing glutamate-induced retinal cell migration in a concentration effective to reduce such migration.Type: ApplicationFiled: July 6, 2004Publication date: September 1, 2005Applicant: Allergan Sales, Inc.Inventor: Evan Dreyer
-
Publication number: 20050100973Abstract: The present invention provides a nucleic acid molecule which contains a nucleotide sequence encoding a SNAP-25 substrate which includes (i) a green fluorescent protein; (ii) a first partner of an affinity couple; and (iii) a portion of SNAP-25 that includes a BoNT/A, BoNT/C1 or BoNT/E recognition sequence containing a cleavage site, where the cleavage site intervenes between the green fluorescent protein and the first partner of the affinity couple. Further provided herein is a nucleic acid molecule which contains a nucleotide sequence encoding a tagged toxin substrate which includes (i) a fluorescent protein; (ii) a first partner of an affinity couple; and (iii) a clostridial toxin recognition sequence containing a cleavage site, where the cleavage site intervenes between the fluorescent protein and the first partner of the affinity couple.Type: ApplicationFiled: August 13, 2004Publication date: May 12, 2005Applicant: Allergan Sales, Inc.Inventors: Lance Steward, Marcella Gilmore, Kei Aoki
-
Patent number: 6869610Abstract: Methods for treating a non-spasm caused pain by peripheral administration to a patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin.Type: GrantFiled: July 18, 2002Date of Patent: March 22, 2005Assignee: Allergan Sales, Inc.Inventors: Kei Roger Aoki, Minglei Cui, Stephen W. Jenkins
-
Publication number: 20050019338Abstract: Methods for determining the effect of a Clostridial neurotoxin on muscle are disclosed. In particular, methods for determining a potency and/or diffusion of a neurotoxin based on a nuclear index and/or an amount of muscle atrophy are disclosed. The methods may be used to distinguish two different Clostridial neurotoxins. In certain embodiments, the neurotoxins are obtained from Clostridium botulinum.Type: ApplicationFiled: August 13, 2004Publication date: January 27, 2005Applicant: Allergan Sales, Inc.Inventors: James Holland, Edward Chow
-
Publication number: 20040253673Abstract: The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.Type: ApplicationFiled: December 5, 2003Publication date: December 16, 2004Applicant: Allergan Sales, Inc., Allergan Botox LimitedInventor: James A. Williams
-
Publication number: 20040219637Abstract: The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.Type: ApplicationFiled: December 5, 2003Publication date: November 4, 2004Applicant: Allergan Sales, Inc. Allergan Botox LimitedInventor: James A. Williams
-
Publication number: 20040175435Abstract: Compositions including a liquid medium, a cyclodextrin component and a preservative component which has a reduced tendency to being complexed with the cyclodextrin component. In one embodiment, the preservative component is a chlorite component. Active components, such as pharmaceutically active components or drugs, preferably are included in the compositions.Type: ApplicationFiled: March 15, 2004Publication date: September 9, 2004Applicant: Allergan Sales, Inc.Inventors: Gary J. Beck, Edward D.S. Kerslake, Orest Olejnik
-
Publication number: 20040146532Abstract: Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent are disclosed. The agent may include a clostridial neurotoxin, a fragment or a derivative thereof, attached to a targeting component, wherein the targeting component is selected from a group consisting of compounds which selectively binds at the alpha-2B or alpha-2B/alpha-2C adrenergic receptor subtype(s) as compared to other binding sites, for example, the alpha-2A adrenergic receptor subtype.Type: ApplicationFiled: March 1, 2004Publication date: July 29, 2004Applicant: Allergan Sales, Inc.Inventors: Daniel W. Gil, Kei R. Aoki
-
Publication number: 20040142455Abstract: The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.Type: ApplicationFiled: December 5, 2003Publication date: July 22, 2004Applicant: Allergan Sales, Inc., Allergan Botox LimitedInventor: James A. Williams
-
Publication number: 20040115215Abstract: The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.Type: ApplicationFiled: December 5, 2003Publication date: June 17, 2004Applicant: Allergan Sales, Inc., Allergan Botox LimitedInventor: James A. Williams
-
Publication number: 20040005289Abstract: Ophthalmic compositions include an ophthalmically acceptable carrier component, for example, an aqueous-based carrier, and a plurality of polyanionic component portions having different molecular weights. In one embodiment, the polyanionic component includes a first polyanionic component portion having a first molecular weight; and a second polyanionic component portion having a different second molecular weight. Each of the first and second polyanionic component portions is present in an amount effective to provide lubrication to an eye when the composition is administered to an eye. Methods of making and using such compositions are also disclosed.Type: ApplicationFiled: December 14, 2001Publication date: January 8, 2004Applicant: Allergan Sales, IncInventors: James N. Chang, Teresa H. Kuan
-
Publication number: 20030228632Abstract: Stable cell lines which express retinoid receptors and the insulin receptor are prepared and are useful in identifying agonists and antagonists of retinoid receptors. Agonists and antagonists of the RXR receptor can be determined using the cell lines of the invention which are producers of RXR alone; agonists and antagonists of other retinoid receptors can be determined using cell lines transfected with RXR and the desired retinoid receptor.Type: ApplicationFiled: May 8, 2001Publication date: December 11, 2003Applicant: Allergan Sales, Inc.Inventors: Jyotirmoy Kusari, Sheila X. Zhou, Hongzhi Liu, Ramilla O. Lewis, Roshantha A. Chandraratna
-
Publication number: 20030219462Abstract: Natural and modified neurotoxins and isolated neurotoxin compositions are described. The neurotoxins may include one or more structural modifications, wherein the structural modification(s) alters the biological persistence, such as the biological half-life and/or a biological activity of the modified neurotoxin relative to an identical neurotoxin without the structural modification(s). In one embodiment, methods of making the modified neurotoxin include using recombinant techniques. In another embodiment, methods of using the modified neurotoxin to treat conditions include treating various disorders, neuromuscular aliments and pain.Type: ApplicationFiled: June 4, 2002Publication date: November 27, 2003Applicant: Allergan Sales, IncInventors: Lance E. Steward, Ester Fernandez-Salas, Todd Herrington, Kei Roger Aoki
-
Publication number: 20030219457Abstract: The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A, type B and type E toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of significant endotoxin contamination are provided. The soluble, endotoxin-free recombinant proteins are used as immunogens for the production of vaccines and antitoxins. These vaccines and antitoxins are useful in the treatment of humans and other animals at risk of intoxication with clostridial toxin.Type: ApplicationFiled: October 15, 2002Publication date: November 27, 2003Applicant: Allergan Sales, Inc., Allergan Botox LimitedInventor: James A. Williams
-
Publication number: 20030216745Abstract: An intraocular lens (IOL) insertion system for implanting IOLs into the eye. The insertion system includes an insertion cartridge that receives the IOL and cooperates with a handpiece. The cartridge includes a longitudinal lumen from a loading chamber to an open distal mouth that gradually narrows in dimension so as to fold the IOL into a tube for insertion through an incision in the eye. A distal tip member of a plunger rod in the handpiece enters the loading chamber of the cartridge and urges the IOL therethrough. The distal tip member has a portion that enters the folded IOL and is trapped therein for maximum control of IOL advancement. A soft tip, such as silicone, may cover a longitudinally extending portion of the distal tip to effect the IOL trapping. The distal tip member further has a portion that engages and pushes the IOL optic.Type: ApplicationFiled: May 14, 2002Publication date: November 20, 2003Applicant: Allergan Sales, Inc.Inventors: Daniel G. Brady, Harish C. Makker
-
Publication number: 20030211121Abstract: Methods for treating psychiatric disorders include intracranial administration of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin type A, to a human patient.Type: ApplicationFiled: May 10, 2002Publication date: November 13, 2003Applicant: Allergan Sales, Inc.Inventor: Stephen Donovan
-
Patent number: 6645496Abstract: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.Type: GrantFiled: February 28, 2001Date of Patent: November 11, 2003Assignee: Allergan Sales, Inc.Inventors: K. Roger Aoki, Michael W. Grayston, Steven R. Carlson, Judith M. Leon
-
Patent number: 6641834Abstract: Compositions useful for improving effectiveness of alpha-2-adrenergic agonist components include carrier components, alpha-2-adrenergic agonist components, solubility enhancing components which aid in solubilizing the alpha-2-adrenergic agonist components. In one embodiment, the alpha-2-adrenergic agonist components include alpha-2-adrenergic agonists. In another embodiment, the solubility enhancing components include carboxymethylcellulose.Type: GrantFiled: September 6, 2002Date of Patent: November 4, 2003Assignee: Allergan Sales, Inc.Inventors: Orest Olejnik, Edward D. S. Kerslake